Kura Oncology, INC Form 4 insider transactions

Kura Oncology's Chief Commercial Officer, Brian T. Powl, reported the acquisition of 48,900 restricted stock units and a subsequent sale of 8,887 shares to cover tax obligations.

Kura Oncology's Chief Medical Officer, Mollie Leoni, sold shares to cover taxes following the vesting of performance-based restricted stock units tied to a development milestone.

Kura Oncology's SVP of Finance and Accounting, Thomas Doyle, sold shares to cover taxes after performance-based restricted stock units vested due to a development milestone.

Kura Oncology's Chief Operating Officer, Kathleen Ford, reported the vesting of performance-based restricted stock units and a subsequent sell-to-cover transaction for tax obligations.

Kura Oncology's Chief Commercial Officer, Brian T. Powl, sold 8,891 shares of common stock to cover tax liabilities from a recent restricted stock unit vesting.

Kura Oncology's Chief Legal Officer, Teresa Bair, sold 8,805 shares of common stock to cover taxes following the vesting of 48,900 performance-based restricted stock units.

Kura Oncology's COO, Kathleen Ford, sold shares to cover taxes after performance-based restricted stock units vested due to a development milestone.

Kura Oncology's Chief Medical Officer, Mollie Leoni, reported the vesting of 82,500 performance-based restricted stock units and a subsequent sale of 12,314 shares to cover tax obligations.

Kura Oncology's President and CEO, Troy Edward Wilson, sold 36,615 shares of common stock to cover taxes following the vesting of performance-based restricted stock units.

Kura Oncology's SVP of Finance and Accounting, Thomas Doyle, reported the vesting of performance-based restricted stock units following a milestone achievement and a subsequent tax-related share sale.

Kura Oncology's President and CEO, Troy Edward Wilson, acquired 50,000 shares of common stock at a weighted average price of $8.2029.

Kura Oncology's CEO, Troy Wilson, recently purchased shares of the company's stock in multiple transactions.

Kura Oncology, Inc. Director Diane L. Parks was granted options to purchase 28,500 shares of common stock at an exercise price of $6.57, vesting in one year.

Kura Oncology, Inc. Director Michael Vasconcelles was granted 28,500 stock options with an exercise price of $6.57, vesting in one year, as part of a Rule 10b5-1 plan.

Kura Oncology, Inc. Director Carol Schafer was granted 28,500 stock options with an exercise price of $6.57, vesting in one year.

Kura Oncology's Director, Faheem Hasnain, was granted 28,500 stock options with an exercise price of $6.57, aligning his interests with shareholder value.

Kura Oncology, Inc. Director Thomas Malley was granted 28,500 stock options with an exercise price of $6.57, vesting on the one-year anniversary of the grant date.

Kura Oncology, Inc. director Mary T. Szela was granted 28,500 stock options with an exercise price of $6.57, vesting in full on June 5, 2026.

Kura Oncology Director Helen Collins was granted 28,500 stock options with an exercise price of $6.57, aligning her interests with long-term shareholder value.

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, reports a stock purchase and sale executed under a pre-arranged Rule 10b5-1 trading plan and the Employee Stock Purchase Plan.

Kathleen Ford, COO of Kura Oncology, reports the purchase of 1,558 shares of common stock at an average price of $6.2756, executed under a pre-arranged 10b5-1 trading plan.

Director Faheem Hasnain of Kura Oncology, Inc. reports stock transactions, including acquisitions and disposals, under a pre-arranged Rule 10b5-1 trading plan.

Thomas James Doyle, SVP of Finance & Accounting at Kura Oncology, sold a portion of his shares to cover taxes associated with the vesting of restricted stock units.

Mollie Leoni, Chief Medical Officer of Kura Oncology, sold a total of 4,963 shares of common stock on January 28, 2025, to cover taxes associated with the vesting of restricted stock units.

Kura Oncology's Chief Legal Officer, Teresa Bair, sold shares to cover taxes related to the vesting of restricted stock units.

Kura Oncology's Chief Operating Officer, Kathleen Ford, sold 1,817 shares of common stock to cover taxes related to a vesting of restricted stock units.

Kura Oncology's Chief Scientific Officer, Francis Burrows, sold shares to cover taxes related to the vesting of restricted stock units.

Brian T. Powl, Chief Commercial Officer of Kura Oncology, sold 1,583 shares of common stock to cover taxes related to a vesting of restricted stock units.

Mollie Leoni, Chief Medical Officer of Kura Oncology, reported the acquisition of restricted stock units and stock options.

Kura Oncology's Chief Scientific Officer, Francis Burrows, was granted options to purchase 185,000 shares of common stock.